Acute behavioural disturbance in psychiAcute behavioural disturbance in psychiatric patients may require urgent treatment. atric patients may require urgent treatment. This may result from psychotic symptoms, This may result from psychotic symptoms, such as persecutory delusions or command such as persecutory delusions or command hallucinations, or alternatively from nonhallucinations, or alternatively from nonpsychotic symptoms such as high levels of psychotic symptoms such as high levels of anxiety (Atakan & Davies, 1997) . The anxiety (Atakan & Davies, 1997) . The clinical management of such problems clinical management of such problems involves many elements including risk involves many elements including risk assessment to try to prevent the escalation assessment to try to prevent the escalation of disturbed behaviour, 'talking down' of disturbed behaviour, 'talking down' patients, containment and the minimisation patients, containment and the minimisation of risk to others. If non-pharmacological of risk to others. If non-pharmacological methods have failed to resolve the situation methods have failed to resolve the situation and oral medication is not an option, then and oral medication is not an option, then rapid tranquillisation with intramuscular rapid tranquillisation with intramuscular or intravenous antipsychotics, benzodiazeor intravenous antipsychotics, benzodiazepines or other sedative drugs may be indipines or other sedative drugs may be indicated. Tranquillisation literally means cated. Tranquillisation literally means calming without sedation. Clearly in situacalming without sedation. Clearly in situations of acute behavioural disturbance, tions of acute behavioural disturbance, sedation may also be an appropriate goal. sedation may also be an appropriate goal. This review concentrates solely on parentThis review concentrates solely on parenteral pharmacological methods of both eral pharmacological methods of both calming and sedating patients, jointly calming and sedating patients, jointly referred to as 'rapid tranquillisation'. The referred to as 'rapid tranquillisation'. The review covers only methods of rapid review covers only methods of rapid tranquillisation for acutely disturbed tranquillisation for acutely disturbed patients and not the treatment of more patients and not the treatment of more specific conditions. specific conditions.
PAST PR ACTICE PAST PR ACTICE
A survey of prescribing practices in a general A survey of prescribing practices in a general psychiatric in-patient setting found the psychiatric in-patient setting found the most commonly prescribed medications most commonly prescribed medications for rapid tranquillisation to be diazepam for rapid tranquillisation to be diazepam and haloperidol, followed by droperidol and haloperidol, followed by droperidol and chlorpromazine (Pilowsky and chlorpromazine (Pilowsky et al et al, 1992) . , 1992). Similar findings were made in a survey of Similar findings were made in a survey of 67 consultants and senior registrars in psy-67 consultants and senior registrars in psychiatry in the Manchester area of the UK. chiatry in the Manchester area of the UK. This study found 90% of clinicians would This study found 90% of clinicians would use an antipsychotic drug: 49% would use use an antipsychotic drug: 49% would use haloperidol, 34% chlorpromazine and haloperidol, 34% chlorpromazine and 15% droperidol. This would be used by 15% droperidol. This would be used by 24% of the total sample in combination 24% of the total sample in combination with a benzodiazapine -diazepam or with a benzodiazapine -diazepam or lorazepam (Simpson & Anderson, 1996) . lorazepam (Simpson & Anderson, 1996) . If the drug needed to be administered If the drug needed to be administered parenterally, 80% of the clinicians surveyed parenterally, 80% of the clinicians surveyed indicated that they would give it intraindicated that they would give it intramuscularly. The short-acting depot zuclomuscularly. The short-acting depot zuclopenthixol acetate was the initial drug of penthixol acetate was the initial drug of choice for 10%, while 34% indicated they choice for 10%, while 34% indicated they would use this if their first-line antiwould use this if their first-line antipsychotic agent was ineffective (Simpson psychotic agent was ineffective (Simpson & Anderson, 1996) . & Anderson, 1996) .
These treatments are not without sideThese treatments are not without sideeffects. A survey of around 100 incidents effects. A survey of around 100 incidents of rapid tranquillisation conducted by of rapid tranquillisation conducted by Pilowski Pilowski et al et al (1992) found few adverse (1992) found few adverse events, but those reported were potentially events, but those reported were potentially serious, including cardiorespiratory pro serious, including cardiorespiratory prob-blems, with cardiac arrests in 2% and cardiolems, with cardiac arrests in 2% and cardiovascular complications in 3%. Although vascular complications in 3%. Although not reported in this study, dystonic renot reported in this study, dystonic reactions are not uncommon in patients actions are not uncommon in patients administered an intramuscular antiadministered an intramuscular antipsychotic. These reactions can be severe, psychotic. These reactions can be severe, and extremely unpleasant; they may exacerand extremely unpleasant; they may exacerbate disturbed behaviour (Royal College of bate disturbed behaviour (Royal College of Psychiatrists Psychopharmacology SubPsychiatrists Psychopharmacology Subgroup, 1997) and in newly diagnosed cases group, 1997) and in newly diagnosed cases of schizophrenia may have long-term of schizophrenia may have long-term consequences due to lack of compliance consequences due to lack of compliance with treatment (van Harten with treatment (van Harten et al et al, 1999) . , 1999). There has been little research into the There has been little research into the effectiveness of rapid tranquillisation effectiveness of rapid tranquillisation treatments. However, what work has treatments. However, what work has been conducted confirms the effectiveness been conducted confirms the effectiveness of antipsychotics (usually haloperidol or of antipsychotics (usually haloperidol or droperidol) and benzodiazepines (usually droperidol) and benzodiazepines (usually lorazepam or diazepam) alone and espelorazepam or diazepam) alone and especially in combination (Garza-Trevino cially in combination (Garza-Trevino et et al al, 1989) . This led to the development of , 1989). This led to the development of a number of guidelines (Atakan & Davies, a number of guidelines (Atakan & Davies, 1997; Kerr & Taylor, 1997; Royal College 1997; Kerr & Taylor, 1997; Royal College of Psychiatrists Psychopharmacology Subof Psychiatrists Psychopharmacology SubGroup, 1977) . These recommend non- Group, 1977) . These recommend nonpharmacological and oral therapy (when pharmacological and oral therapy (when liquid and rapidly dissolving formulations liquid and rapidly dissolving formulations may be particularly useful) before embarkmay be particularly useful) before embarking on parenteral treatment. However, if ing on parenteral treatment. However, if the latter proves necessary, two optionsthe latter proves necessary, two optionsintramuscular droperidol and lorazepam, intramuscular droperidol and lorazepam, or intravenous haloperidol and diazeor intravenous haloperidol and diazepam -are recommended in the first pam -are recommended in the first instance, with a repeat treatment 10 minutes instance, with a repeat treatment 10 minutes after intravenous treatment and 30 minutes after intravenous treatment and 30 minutes after intramuscular treatment in the event after intramuscular treatment in the event of non-response. Intravenous administraof non-response. Intravenous administration to acutely behaviourally disturbed tion to acutely behaviourally disturbed patients is no mean undertaking, though it patients is no mean undertaking, though it can be highly effective when administered can be highly effective when administered in appropriate circumstances by wellin appropriate circumstances by welltrained staff. The more rapid absorption trained staff. The more rapid absorption 4 8 5 4 8 5 (Resnick & Burton, 1984) . patients (Resnick & Burton, 1984) .
RECENT PROBLEMS RECENT PROBLEMS
Concern has been growing about the carConcern has been growing about the cardiac effects of antipsychotics (Thomas, diac effects of antipsychotics (Thomas, 1994) . In 1999, the newly introduced 1994). In 1999, the newly introduced atypical antipsychotic sertindole was withatypical antipsychotic sertindole was withdrawn by the manufacturer following drawn by the manufacturer following concerns about its electrocardiographic concerns about its electrocardiographic (ECG) effects and a number of sudden (ECG) effects and a number of sudden deaths of patients on this medication. A deaths of patients on this medication. A change in the rate-corrected QT interval change in the rate-corrected QT interval (QT (QT c c ) in the ECG with medication may be ) in the ECG with medication may be an index of cardiotoxicity. Several psychoan index of cardiotoxicity. Several psychotropic drugs are associated with protropic drugs are associated with prolongation of the QT longation of the QT c c (Thomas, 1994; (Thomas, 1994 k/ /m mo on ni it to or rs sa af fe eq qu ua al lm me ed d/ /s sa af fe et ty ym me es ss sa ag ge es s /droleptan.htm). The data concerning the /droleptan.htm). The data concerning the risk of QT risk of QT c c prolongation with droperidol prolongation with droperidol were obtained from patients treated for a were obtained from patients treated for a minimum of 2 weeks with the oral formuminimum of 2 weeks with the oral formulation (Reilly lation (Reilly et al et al, 2000) . However, the , 2000). However, the company decided to withdraw the parentcompany decided to withdraw the parenteral formulation for commercial reasons. eral formulation for commercial reasons. As a result, the mainstay of the pharmacoAs a result, the mainstay of the pharmacological armamentarium for rapid tranlogical armamentarium for rapid tranquillisation is no longer available. quillisation is no longer available.
CURRENT OPTIONS CURRENT OPTIONS
The choice of medication in a parenteral The choice of medication in a parenteral formulation in the UK is limited. Promazine formulation in the UK is limited. Promazine and prochlorperazine are available for and prochlorperazine are available for injection but the former has a weak antiinjection but the former has a weak antipsychotic effect and the latter is primarily psychotic effect and the latter is primarily used as an anti-emetic. Beyond these used as an anti-emetic. Beyond these two drugs, the only other antipsychotic two drugs, the only other antipsychotic options available are chlorpromazine, options available are chlorpromazine, haloperidol and zuclopenthixol acetate. In haloperidol and zuclopenthixol acetate. In addition, parenteral formulations of the addition, parenteral formulations of the benzodiaze benzodiazepines lorazepam and diazepam pines lorazepam and diazepam are available. are available.
Chlorpromazine Chlorpromazine
Chlorpromazine has many disadvantages Chlorpromazine has many disadvantages because its intramuscular injection is painbecause its intramuscular injection is painful and it has a propensity for causing hypoful and it has a propensity for causing hypotension, particularly in the elderly (Swett tension, particularly in the elderly (Swett et et al al, 1977; Musey , 1977; Musey et al et al, 1986) . In addition, , 1986). In addition, an association between high-dose chloran association between high-dose chlorpromazine and sudden death has been promazine and sudden death has been mooted (Jusic & Lader, 1994) . Conmooted (Jusic & Lader, 1994) . Consequently, chlorpromazine is not recomsequently, chlorpromazine is not recommended for intramuscular use (Royal mended for intramuscular use (Royal College of Psychiatrists PsychopharmaCollege of Psychiatrists Psychopharmacology Sub-group, 1997). It also carries a cology Sub-group, 1997). It also carries a risk of prolonged unconsciousness with risk of prolonged unconsciousness with intravenous administration (Quenstedt intravenous administration (Quenstedt et et al al, 1992) .
, 1992).
Haloperidol Haloperidol
Haloperidol given intramuscularly appears Haloperidol given intramuscularly appears to be effective for rapid tranquillisation to be effective for rapid tranquillisation (Neborsky (Neborsky et al et al, 1981) . While it is generally , 1981). While it is generally thought to be safe and is recommended in thought to be safe and is recommended in previous guidelines (Atakan & Davies, previous guidelines (Atakan & Davies, 1997; Kerr & Taylor, 1997) , serious 1997; Kerr & Taylor, 1997), serious adverse events have been described includadverse events have been described including sudden death (Jusic & Lader, 1994) , ing sudden death (Jusic & Lader, 1994) , cardiac arrests (Goldney cardiac arrests (Goldney et al et al, 1986) and , 1986 ) and neuroleptic malignant syndrome (Konikoff neuroleptic malignant syndrome (Konikoff et al et al, 1984) . The study that demonstrated , 1984) . The study that demonstrated increases in QT increases in QT c c associated with thioriassociated with thioridazine and droperidol found an association dazine and droperidol found an association with haloperidol just short of significance with haloperidol just short of significance ( (P P¼0. ) generated a flurry of correspondence 2000) generated a flurry of correspondence ( (h ht tt tp p: :/ // /w ww ww w. .b bm mj j. .c co om m/ /c cg gi i/ /c co on nt te en nt t/ /f fu ul ll l/ /3 32 21/ 1/ 7273/1371) from patient organisations and 7273/1371) from patient organisations and psychiatrists because it recommended the psychiatrists because it recommended the use of typical agents in the acute phase of use of typical agents in the acute phase of schizophrenia. Much of the criticism schizophrenia. Much of the criticism centred on the unfavourable side-effect centred on the unfavourable side-effect profile of typical drugs, especially extraprofile of typical drugs, especially extrapyramidal symptoms. Such symptoms seen pyramidal symptoms. Such symptoms seen in schizophrenia are not solely related to in schizophrenia are not solely related to antipsychotic use. Dyskinesia has been antipsychotic use. Dyskinesia has been reported in patients who have never reported in patients who have never received antipsychotic medication, with a received antipsychotic medication, with a prevalence that increases with age (Fenton, prevalence that increases with age (Fenton, 2000) . A study from India of people with 2000). A study from India of people with schizophrenia found that never-medicated schizophrenia found that never-medicated patients aged over 50 years suffered from patients aged over 50 years suffered from rates of parkinsonism, akathisia and dysrates of parkinsonism, akathisia and dyskinesia over twice those seen in agekinesia over twice those seen in agematched control subjects (McCreadie matched control subjects (McCreadie et et al al, 1996) . This suggests that disturbance , 1996). This suggests that disturbance of basal ganglia function might be an of basal ganglia function might be an inherent factor in the pathology of schizoinherent factor in the pathology of schizophrenia, or at least one that develops over phrenia, or at least one that develops over time. The use of drugs that compound these time. The use of drugs that compound these problems, particularly haloperidol (which problems, particularly haloperidol (which is contraindicated in patients with 'basal is contraindicated in patients with 'basal ganglia disease' according to the ganglia disease' according to the British British National Formulary National Formulary; British Medical ; British Medical Association & Royal Pharmaceutical Association & Royal Pharmaceutical Society of Great Britain, (2000)), therefore Society of Great Britain, (2000)), therefore requires caution, particularly in the elderly. requires caution, particularly in the elderly.
Zuclopenthixol Zuclopenthixol
Some psychiatrists use the short-acting Some psychiatrists use the short-acting depot antipsychotic zuclopenthixol acetate depot antipsychotic zuclopenthixol acetate for rapid tranquillisation (Simpson & for rapid tranquillisation (Simpson & Anderson, 1996) . Because of the potential Anderson, 1996) . Because of the potential dangers of injecting a previously untreated dangers of injecting a previously untreated patient with a drug that has a long half-life, patient with a drug that has a long half-life, this practice is contrary to a Royal College this practice is contrary to a Royal College of Psychiatrists' consensus statement that of Psychiatrists' consensus statement that recommends its use only when 'circumrecommends its use only when 'circumstances are exceptional' in antipsychoticstances are exceptional' in antipsychoticnaive patients (Thompson, 1994) . Previous naive patients (Thompson, 1994) . Previous guidelines recommended the use of zucloguidelines recommended the use of zuclopenthixol acetate only when initial control penthixol acetate only when initial control of disturbed behaviour had at least partially of disturbed behaviour had at least partially been established with a short-acting antibeen established with a short-acting antipsychotic and/or a benzodiazepine (Atakan psychotic and/or a benzodiazepine (Atakan & Davies, 1997; Kerr & Taylor, 1997 
Benzodiazepines Benzodiazepines
Benzodiazepines can be used for rapid tranBenzodiazepines can be used for rapid tranquillisation owing to their sedative and quillisation owing to their sedative and anxiolytic properties. In addition, these anxiolytic properties. In addition, these drugs enhance gamma-aminobutyric acid drugs enhance gamma-aminobutyric acid activity which can inhibit dopamineactivity which can inhibit dopaminemediated transmission, possibly providing mediated transmission, possibly providing a direct antipsychotic effect (Stimmel, a direct antipsychotic effect (Stimmel, 1996) . The most serious adverse effect of 1996). The most serious adverse effect of benzodiazepines is respiratory depression benzodiazepines is respiratory depression when high doses are given, although this when high doses are given, although this can be readily reversed using the benzocan be readily reversed using the benzodiazepine partial agonist flumazenil. Of diazepine partial agonist flumazenil. Of concern when treating acute behavioural concern when treating acute behavioural disturbance are numerous case reports of disturbance are numerous case reports of behavioural disinhibition with benzodiazebehavioural disinhibition with benzodiazepines (Bond, 1998) . This has been argued pines (Bond, 1998) . This has been argued to be a particular risk in patients with to be a particular risk in patients with pre-existing poor impulse control (Van der pre-existing poor impulse control (Van der Bijl & Roelofse, 1991; Bond, 1998) or Bijl & Roelofse, 1991; Bond, 1998) or hostility, and when using high doses of hostility, and when using high doses of benzodiazepines (Rothschild, 1992) . Conbenzodiazepines (Rothschild, 1992). Conversely, it has been suggested that the inciversely, it has been suggested that the incidence of aggressive dyscontrol following dence of aggressive dyscontrol following treatment with benzodiazepines is less than treatment with benzodiazepines is less than 1% with no predictive indicators (Dietch & 1% with no predictive indicators (Dietch & Jennings, 1988 ) and a controlled study has Jennings, 1988) and a controlled study has not shown disinhibition to be a side-effect not shown disinhibition to be a side-effect of benzodiazepine use (Rothschild of benzodiazepine use (Rothschild et al et al, , 2000) . Some of these discrepancies may 2000). Some of these discrepancies may relate to the difficult task of differentiating relate to the difficult task of differentiating behavioural dyscontrol from the behaviour behavioural dyscontrol from the behaviour for which the benzodiazepine is being for which the benzodiazepine is being administered in the first place. Nevertheadministered in the first place. Nevertheless, it is prudent to exercise care and doses less, it is prudent to exercise care and doses should be kept as low as practically should be kept as low as practically possible (Van der Bijl & Roelofse, 1991) . possible (Van der Bijl & Roelofse, 1991) . Another practical issue relates to concern Another practical issue relates to concern that around 20% of psychiatric patients that around 20% of psychiatric patients who are first given benzodiazepines while who are first given benzodiazepines while in hospital are still prescribed them at in hospital are still prescribed them at discharge (Summers & Brown, 1998) . discharge (Summers & Brown, 1998) . Good clinical practice always involves Good clinical practice always involves repeated assessment of prescribed medirepeated assessment of prescribed medication so that drugs used for rapid trancation so that drugs used for rapid tranquillisation are not continued indefinitely quillisation are not continued indefinitely on an 'as required' basis orally when no on an 'as required' basis orally when no longer indicated. This is especially importlonger indicated. This is especially important with drugs such as benzodiazepines that ant with drugs such as benzodiazepines that carry a high risk of dependency. However, carry a high risk of dependency. However, these concerns notwithstanding, the wide these concerns notwithstanding, the wide therapeutic index of these drugs makes therapeutic index of these drugs makes them useful alternatives to antipsychotics them useful alternatives to antipsychotics for rapid tranquillisation. Diazepam for rapid tranquillisation. Diazepam emulsion is effective when given intraemulsion is effective when given intravenously (Lerner venously (Lerner et al et al, 1979) , but is not , 1979), but is not appropriate for intramuscular use because appropriate for intramuscular use because of its erratic absorption (Gamble of its erratic absorption (Gamble et al et al, , 1975) . Consequently, intramuscular loraze-1975) . Consequently, intramuscular lorazepam, which is better absorbed (Greenblatt pam, which is better absorbed (Greenblatt et al et al, 1979) , is the benzodiazepine of choice , 1979), is the benzodiazepine of choice (Atakan & Davies, 1997; Kerr & Taylor, (Atakan & Davies, 1997; Kerr & Taylor, 1997) . 1997).
FUTURE POSSIBILITIES FUTURE POSSIBILITIES
The advent of atypical antipsychotic drugs The advent of atypical antipsychotic drugs has led to significant changes in the treathas led to significant changes in the treatment of schizophrenia, not least because ment of schizophrenia, not least because of the greater patient tolerability of these of the greater patient tolerability of these drugs compared with the typical antidrugs compared with the typical antipsychotics (Barnes & McPhillips, 1999) . psychotics (Barnes & McPhillips, 1999) . At present, only oral preparations are availAt present, only oral preparations are available for use. The advent of injectable able for use. The advent of injectable extended-release forms of the atypical antiextended-release forms of the atypical antipsychotic agents may be a useful developpsychotic agents may be a useful development in view of the unpleasant side-effects ment in view of the unpleasant side-effects that can occur with current drugs in such that can occur with current drugs in such formulations (Davis formulations (Davis et al et al, 1994; Weiden , 1994; Weiden et et al al, 1996; Fleischhacker & Hummer, , 1996; Fleischhacker & Hummer, 1997) . Rapid-acting injectable forms of 1997). Rapid-acting injectable forms of atypical antipsychotic drugs may also atypical antipsychotic drugs may also provide valuable new treatment options. provide valuable new treatment options.
Olanzapine Olanzapine
Two double-blind, randomised, controlled Two double-blind, randomised, controlled trials have now been conducted examining trials have now been conducted examining the effect of intramuscular olanzapine in pathe effect of intramuscular olanzapine in patients with acute behavioural disturbance. tients with acute behavioural disturbance.
The first trial examined, in 270 patients, The first trial examined, in 270 patients, doses of 2.5-10 mg compared with halodoses of 2.5-10 mg compared with haloperidol 7.5 mg and placebo (Wright peridol 7.5 mg and placebo (Wright et al et al, , 2001 (Wright et al et al, , 2001b . All the active treatments were ). All the active treatments were more effective at reducing the behavioural more effective at reducing the behavioural disturbance than placebo, with a dosedisturbance than placebo, with a doseeffect relationship for olanzapine. Dosages effect relationship for olanzapine. Dosages of 7.5 mg and 10 mg of olanzapine were of 7.5 mg and 10 mg of olanzapine were found to be as good as or better than halofound to be as good as or better than haloperidol 7.5 mg. No significant serious peridol 7.5 mg. No significant serious adverse event was seen with any of the adverse event was seen with any of the treatments, but haloperidol caused signifitreatments, but haloperidol caused significantly more episodes of acute dystonia cantly more episodes of acute dystonia and tremor than olanzapine. There was no and tremor than olanzapine. There was no significant increase in QT significant increase in QT c c intervals in paintervals in patients with any treatment, in line with tients with any treatment, in line with previous data regarding oral treatment in previous data regarding oral treatment in large numbers of patients (Czekalla large numbers of patients (Czekalla et al et al, , 2001 ). The findings in acutely disturbed 2001). The findings in acutely disturbed patients were broadly confirmed in a secpatients were broadly confirmed in a second study comparing olanzapine 10 mg ond study comparing olanzapine 10 mg with haloperidol 7.5 mg and placebo in with haloperidol 7.5 mg and placebo in 311 patients (Wright 311 patients (Wright et al et al, 2001 (Wright et al et al, , 2001a . This ). This study demonstrated a more rapid onset of study demonstrated a more rapid onset of action of olanzapine compared with haloaction of olanzapine compared with haloperidol, with the former producing signifiperidol, with the former producing significantly greater reductions in disturbed cantly greater reductions in disturbed behaviour 30 minutes after injection than behaviour 30 minutes after injection than haloperidol. In addition, olanzapine was haloperidol. In addition, olanzapine was associated with significantly fewer extraassociated with significantly fewer extrapyramidal side-effects, including dystonia. pyramidal side-effects, including dystonia.
Ziprasidone Ziprasidone
Ziprasidone is an atypical antipsychotic Ziprasidone is an atypical antipsychotic agent that is yet to be launched in the agent that is yet to be launched in the United Kingdom in any formulation. HowUnited Kingdom in any formulation. However, an intramuscular formulation of the ever, an intramuscular formulation of the drug exists. An open-label flexible dose drug exists. An open-label flexible dose comparison with haloperidol in 132 comparison with haloperidol in 132 patients found ziprasidone 5-20 mg to be patients found ziprasidone 5-20 mg to be as good as or better than haloperidol 2.5-as good as or better than haloperidol 2.5-10 mg in reducing agitation (Brook 10 mg in reducing agitation (Brook et al et al, , 2000) . This study reported that ziprasidone 2000). This study reported that ziprasidone produced significantly fewer extraproduced significantly fewer extrapyramidal side-effects compared with halopyramidal side-effects compared with haloperidol. The registration of ziprasidone in peridol. The registration of ziprasidone in the USA was delayed because of concerns the USA was delayed because of concerns that the drug led to prolongation of the that the drug led to prolongation of the QT QT c c interval. 
CONCLUSION CONCLUSION
Options for the pharmacological manageOptions for the pharmacological management of acutely disturbed behaviour have ment of acutely disturbed behaviour have recently become restricted owing to the recently become restricted owing to the withdrawal of droperidol. Haloperidol is withdrawal of droperidol. Haloperidol is an alternative antipsychotic option recoman alternative antipsychotic option recommended in a number of current guidelines. mended in a number of current guidelines. However, caution is advised regarding the However, caution is advised regarding the use of parenteral haloperidol (especially use of parenteral haloperidol (especially intravenously) in the light of an increasing intravenously) in the light of an increasing awareness of the cardiotoxic effects of awareness of the cardiotoxic effects of some antipsychotic drugs and the propensome antipsychotic drugs and the propensity of haloperidol to cause extrapyramidal sity of haloperidol to cause extrapyramidal side-effects. Given these concerns, clinical side-effects. Given these concerns, clinical experience of the use of intramuscular experience of the use of intramuscular formulations of atypical antipsychotic formulations of atypical antipsychotic drugs is awaited with interest so that their drugs is awaited with interest so that their place in therapy can be fully evaluated. In place in therapy can be fully evaluated. In the meantime, the current gap in our armathe meantime, the current gap in our armamentarium is probably best filled by an mentarium is probably best filled by an increased use of benzodiazepines, partiincreased use of benzodiazepines, particularly intramuscular lorazepam or intracularly intramuscular lorazepam or intravenous diazepam. Caution needs to be venous diazepam. Caution needs to be exercised when using these drugs, although exercised when using these drugs, although the risk the risk of induced behavioural disinhibiof induced behavioural disinhibition appears to be low. At higher doses, tion appears to be low. At higher doses, respiratory depression can occur but this respiratory depression can occur but this can be readily reversed with appropriate can be readily reversed with appropriate treatment. Resuscitation equipment and treatment. Resuscitation equipment and flumazenil should be readily available, espeflumazenil should be readily available, especially if using the intravenous route. In cially if using the intravenous route. In addition, regular reviews of treatment addition, regular reviews of treatment are essential to prevent medication used are essential to prevent medication used for rapid tranquillisation being continued for rapid tranquillisation being continued inappropriately. inappropriately. 
